Type your tag names separated by a space and hit enter

Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97.

Abstract

In November 1996, 11 lots of one U.S. manufacturer's 1996-97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer's vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996-97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer > or = 1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 (p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Influenza Branch, Centers for Disease Control and Prevention, Mail stop A-32, 1600 Clifton Road, Atlanta, GA 30333, USA.

    , , , , , , , , , ,

    Source

    Vaccine 18:11-12 2000 Jan 06 pg 1103-9

    MeSH

    Aged
    Aged, 80 and over
    Antibodies, Viral
    Female
    Hemagglutination Inhibition Tests
    Humans
    Influenza Vaccines
    Male
    Nursing Homes
    Time Factors
    Vaccination

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    10590332

    Citation

    Buxton Bridges, C, et al. "Decreased Antibody Response Among Nursing Home Residents Who Received Recalled Influenza Vaccine and Results of Revaccination, 1996-97." Vaccine, vol. 18, no. 11-12, 2000, pp. 1103-9.
    Buxton Bridges C, Fukuda K, Holman RC, et al. Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. Vaccine. 2000;18(11-12):1103-9.
    Buxton Bridges, C., Fukuda, K., Holman, R. C., De Guzman, A. M., Hodder, R. A., Gomolin, I. H., ... Cox, N. J. (2000). Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. Vaccine, 18(11-12), pp. 1103-9.
    Buxton Bridges C, et al. Decreased Antibody Response Among Nursing Home Residents Who Received Recalled Influenza Vaccine and Results of Revaccination, 1996-97. Vaccine. 2000 Jan 6;18(11-12):1103-9. PubMed PMID: 10590332.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. AU - Buxton Bridges,C, AU - Fukuda,K, AU - Holman,R C, AU - De Guzman,A M, AU - Hodder,R A, AU - Gomolin,I H, AU - Galligan,G K, AU - Leib,H B, AU - Gallo,R J, AU - Regnery,H L, AU - Arden,N H, AU - Cox,N J, PY - 1999/12/11/pubmed PY - 1999/12/11/medline PY - 1999/12/11/entrez SP - 1103 EP - 9 JF - Vaccine JO - Vaccine VL - 18 IS - 11-12 N2 - In November 1996, 11 lots of one U.S. manufacturer's 1996-97 trivalent influenza vaccine were voluntarily recalled because of decreasing potency of the A/Nanchang/933/95 (H3N2) component. Because the elderly are at high risk of developing influenza-related complications, we assessed the postvaccination antibody titers of nursing home residents who received recalled vaccine and assessed the antibody response to revaccination. Blood samples were collected 3 weeks after vaccination from 86 residents at three nursing homes who received recalled vaccine and 86 residents at three other nursing homes who received a different manufacturer's vaccine. Medical records were reviewed. Residents of one nursing home were later revaccinated. Blood samples were collected on the day of revaccination and again in 3 weeks. Serum was tested by hemagglutination inhibition for antibody to all three components of the 1996-97 influenza vaccine. The geometric mean antibody titer (GMT) (33 vs 55; p=0.01) and the percentage of residents with an antibody titer > or = 1:40 (52 vs 67%; p=0.04) to the A/Nanchang/933/95 component were lower among residents who received recalled vaccine compared to those who received non-recalled vaccine, but had similar GMTs against the other two vaccine components. After revaccination, the GMT to A/Nanchang/933/95 increased from 24 on the day of revaccination to 39 (p=0.01) in residents from one nursing home. Therefore, vaccination with the recalled vaccine was associated with lower postvaccination antibody titers to A/Nanchang/933/95, but not against the other two vaccine components. Revaccination was moderately effective in increasing antibody titers. With annual changes in influenza vaccine strains, routine post-release stability testing of influenza vaccine should continue. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/10590332/Decreased_antibody_response_among_nursing_home_residents_who_received_recalled_influenza_vaccine_and_results_of_revaccination_1996_97_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(99)00372-2 DB - PRIME DP - Unbound Medicine ER -